Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Change in Accured Expenses (2021 - 2024)

Opus Genetics (IRD) has disclosed Change in Accured Expenses for 8 consecutive years, with -$116000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Change in Accured Expenses fell 125.16% to -$116000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $123000.0, a 341.18% increase, with the full-year FY2024 number at $5.7 million, up 4513.82% from a year prior.
  • Change in Accured Expenses was -$116000.0 for Q4 2023 at Opus Genetics, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.5 million in Q2 2023 to a low of -$1.5 million in Q3 2023.
  • A 3-year average of -$6916.7 and a median of $25000.0 in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 149700.0% in 2023; the steepest drop was 676.29% in 2023.
  • Opus Genetics' Change in Accured Expenses stood at $612000.0 in 2021, then decreased by 24.67% to $461000.0 in 2022, then crashed by 125.16% to -$116000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Change in Accured Expenses are -$116000.0 (Q4 2023), -$1.5 million (Q3 2023), and $1.5 million (Q2 2023).